Metformin Stada

Metformin Hydrochloride, the active ingredient in Metformin Stada, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose levels in adults with type 2 diabetes and is also employed to improve glycaemic control in pre‑diabetic states.

GNH USA supplies Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Metformin Stada is used to manage disorders of glucose metabolism, primarily within the type 2 diabetes pathway.

- Type 2 diabetes mellitus: improves glycaemic control and reduces HbA1c levels. - Prediabetes (impaired glucose tolerance): delays progression to type 2 diabetes. - Gestational diabetes mellitus (when diet alone is insufficient): assists in achieving target glucose levels.

Metformin Stada may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools occurring especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption leading to low serum levels.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: marked liver enzyme elevations and impaired function. - Hypersensitivity: anaphylactic or severe allergic responses.

Before initiating Metformin Stada, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid use in patients with significant liver disease. - Lactic acidosis risk: discontinue if patient develops severe infection, hypoxia, or dehydration. - Vitamin B12 monitoring: consider periodic testing during long‑term therapy. - Pregnancy and lactation: evaluate risk‑benefit; generally avoid unless clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformin Stada can interact with several medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; withhold metformin before and after imaging. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Other biguanides: additive effect on lactate accumulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance of metformin. - Warfarin: may require INR monitoring.